Research Area
The Peer’s lab work at the interface of materials science, chemistry, molecular biology, and immunology, to discover and validate novel therapeutic targets at the molecular level, and to develop specific molecular medicines for therapeutics and disease management. We are among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in Cancer and inflammation. Our lab was the first to show systemic, cell specific delivery of mRNA molecules.
Team Description
The lab is highly dynamic, multidisciplinary, and focuses on developing targeted vehicles for cell-specific delivery of novel molecular medicines using RNAi, mRNA, saRNA, DNA and novel genome editing strategies. Our goal is to translate academic discoveries into innovative therapeutic modalities. With that in mind, Prof. Peer also founded SPARK Tel Aviv to accelerate cures via academic discoveries. Prof. Peer and his team have done innovative and groundbreaking work in cancer, mostly in brain tumors (Glioblastoma), Ovarian Cancer, and a set of blood cancers (Mantle Cell Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia) and in inflammaotry bowel diseases.
Team Members
Team Show
Publications
1. Rosenblum D, Gutkin A, Kedmi K, Ramishetti S, Veiga N, Jacobi A.M, Schubert M.S, Friedmann- Morvinski D, Cohen Z.R, Behlke M.A, Liberman J, Peer D. (2020) CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances: EABC9450.
2. Uebbing L, Ziller A, Siewert C, Schroer M.A, Blanchet C.E, Svergun D.I, Ramishetti S, Peer D, Sahin U, Haas H and Langguth P. (2020 ) Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir.
3. Nogueira S, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer M.A., Blanchet C.E, Svergun D, Ramishetti R, Peer D, Langguth P, Sahin U, and Haas H. (2020) Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied NanoMaterials.
4. Kon E, Hazan-Halevy I, Rosenblum D, Cohen N, Chatterjee S, Veiga N, Raanani P, Bairey O, Benjamini O, Nagler A, Peer D. (2020) Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics 12(6):E520.
5. Van de Vyver T, Bogaert B, De Backer L, Joris F, Guagliardo R, Van Hoeck J, Merckx P, Van Calenbergh S, Ramishetti S, Peer D, Remaut K, De Smedt SC, and Raemdonck K (2020) Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. ACS Nano. 14(4):4774-4791.
6. Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, Freilich I, Kolik Shmuel L, Danino D, and Peer D (2020) A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv Mater. 30:e1906128.
7. Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y, and Peer D (2020) An Ovarian Spheroid Based Tumor Model that Represents Vascularized Tumors and Enables the Investigation of Nanomedicine Therapeutics. Nanoscale 23;12(3):1894-1903.
8. Veiga N, Goldsmith M, Diesendruck Y, Ramishetti S, Rosenblum D, Elinav E, Behlke MA, Benhar I, and Peer D. (2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release. 313:33-41.
9. Gao M, Deng J, Liu F, Fan A, Wang Y, Wu H, Ding D, Kong D, Wang Z, Peer D, and Zhao Y (2019) Triggered Ferroptotic Polymer Micelles for Reversing Multidrug Resistance to Chemotherapy. Biomaterials. 223:119486.
10. Hazan-Halevy I, Rosenblum D, Ramishetti S, and Peer D (2019) Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. Methods Mol Biol. 1974:151-159.
11. Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M1, Rizzuti I, Palomba R, Zunino P, Duocastella M4, Mizrahy S, Peer D, Decuzzi P (2019) A Tissue Chamber Chip for Assessing Nanoparticle Mobility in the Extravascular Space. Biomed Microdevices. 21(2):41.
12. Edri R, Gal I, Noor N, Harel T, Fleischer S, Adadi N, Green O, Shabat D, Heller L, Shapira A, Gat-Viks I, Peer D, and Dvir T (2019) Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. Adv Mater. 31(1):e1803895.